Zorip DSR 30mg/20mg Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, facilitates gastric motility by enhancing esophageal and gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing. This dual-action capsule is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related dyspeptic conditions where both acid suppression and prokinetic effects are beneficial. Zorip DSR is typically administered orally, with dosing tailored according to clinical response and physician discretion. Caution is advised in patients with underlying cardiac conditions due to the potential for Domperidone to prolong the QT interval. The combination should be used under medical supervision, considering contraindications such as hypersensitivity to either component and concurrent use of medications that may interact adversely. Overall, Zorip DSR offers an effective therapeutic option for symptomatic relief and mucosal protection in acid-peptic disorders.